Results 151 to 160 of about 491,626 (323)
Enhancer‐dependent gene regulation in space, time, and malignancies
International Journal of Cancer, Volume 158, Issue 2, Page 357-367, 15 January 2026.Abstract
Control of cell‐type‐specific gene activation requires the coordinated activity of distal regulatory elements, including enhancers, whose inputs must be temporally integrated. Dysregulation of this regulatory capacity, such as aberrant usage of enhancers, can result in malignant transformation of cells.Belinda Blum, Victoria Dachtler, Angelika Feldmann +2 morewiley +1 more sourceAllogeneic hematopoietic stem cell transplantation in children with lymphoblastic lymphoma
, 2021 А. В. Козлов, И. В. Казанцев, T. V. Yukhta, П. С. Толкунова, A. G. Gevorgyan, I. Yu. Nikolayev, A. N. Galibin, Olga Bogdanova, D. A. Zvyagintseva, М. С. Голенкова, A. N. Shvetsov, V. V. Baykov, Yu. А. Punanov, Еlena V. Morozova, Alexander Kulagin, N. B. Mikhaylova, L. S. Zubarovskaya +16 moreopenalex +2 more sourcesSupplementary Figure 2 from T Cell Receptor Genotyping and <i>HOXA/TLX1</i> Expression Define Three T Lymphoblastic Lymphoma Subsets which Might Affect Clinical Outcome [PDF]
, 2023 Frédéric Baleydier, Anne‐Valérie Decouvelaere, Julie Bergeron, Philippe Gaulard, Danielle Canioni, Yves Bertrand, Stéphane Leprêtre, Barbara Petit, Hervé Dombret, Kheïra Beldjord, Thierry Jo Molina, Vahid Asnafi, Elizabeth Macintyre +12 moreopenalex +1 more sourceTherapeutic targeting of chromatin alterations in leukemia and solid tumors
International Journal of Cancer, Volume 158, Issue 2, Page 382-408, 15 January 2026.Abstract
Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert +7 morewiley +1 more sourceDaratumumab and Nelarabine Treatment as Salvage Therapy for T-Lymphoblastic Lymphoma: A Case Report [PDF]
Gonzalo Castellanos, Laura Pardo, Alberto López‐García, Javier Cornago, José Luis López Lorenzo, Alicia de las Heras, Francisco Javier Díaz, Marta Martínez de Bourio, Eva Castillo, Pilar Llamas, Laura Solán +10 moreopenalex +1 more sourceSupplementary Figure S14 from A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic Lymphoma
, 2023 Xiao-Peng Tian, Ning Su, Liang Wang, Jing‐Kai Huang, Yan‐Hui Liu, Xi Zhang, Huiqiang Huang, Tong-Yu Lin, Shu‐Yun Ma, Hui‐Lan Rao, Mei Li, Fang Liu, Fen Zhang, Li-Ye Zhong, Liang Li, Xiao-Liang Lan, Juan Li, Bing Liao, Zhi-Hua Li, Qiong-Lan Tang, Qiong Liang, Chun‐Kui Shao, Qiong-Li Zhai, Run-Fen Cheng, Qi Sun, Kun Ru, Xia Gu, Xi-Na Lin, Kun Yi, Yue-Rong Shuang, Xiaohong Chen, Wei Dong, Cai Sun, Wei Sang, Hui Liu, Zhi-Gang Zhu, Jun Rao, Qiao‐Nan Guo, Ying Zhou, Xiang-Ling Meng, Yong‐Guan Zhu, Chang-Lu Hu, Yi-Rong Jiang, Ying Zhang, Hong-Yi Gao, Wen-Jun He, Zhongjun Xia, Xue-Yi Pan, Lan Hai, Guo‐Wei Li, Liyan Song, Tiebang Kang, Dan Xie, Qingqing Cai +53 moreopenalex +1 more sourceHyper‐CVAD plus nelarabine in newly diagnosed adult T‐cell acute lymphoblastic leukemia and T‐lymphoblastic lymphoma
American journal of hematology/oncology, 2018 Y. Abaza, Hagop M Kantarjian, S. Faderl, E. Jabbour, N. Jain, D. Thomas, T. Kadia, G. Borthakur, Joseph D Khoury, J. Burger, W. Wierda, S. O'brien, M. Konopleva, A. Ferrajoli, P. Kebriaei, B. Dabaja, S. Kornblau, Y. Alvarado, Naval G. Daver, N. Pemmaraju, P. Bose, P. Thompson, Hind Al Azzawi, M. Kelly, Rebecca E. Garris, P. Jain, G. Garcia-Manero, J. Cortes, F. Ravandi +28 moresemanticscholar +1 more sourceAllogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults With Acute Lymphoblastic Leukemia—A Retrospective, Dual‐Center Study
American Journal of Hematology, Volume 101, Issue 1, Page 16-25, January 2026.ABSTRACT
Survival outcomes for adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) have improved with modern frontline therapies and minimal residual disease (MRD)‐guided strategies. As a result, allogeneic hematopoietic cell transplantation (HCT) is increasingly deferred in first remission (CR1) and used in the relapsed setting.Oren Pasvolsky, Shai Shimony, Rima M. Saliba, Curtis Marcoux, Celina Ledesma, Gabriela Rondon, Priti Tewari, Dristhi Ragoonanan, Nicholas J. Short, Elias Jabbour, Mahasweta Gooptu, Vincent T. Ho, Robert J. Soiffer, Joseph H. Antin, John Koreth, Corey S. Cutler, Jonathan D. Paolino, Christine N. Duncan, Leslie E. Lehmann, Daniel J. DeAngelo, Nitin Jain, Richard Champlin, Elizabeth Shpall, Marlise R. Luskin, Partow Kebriaei +24 morewiley +1 more sourceOptimizing Asparaginase Treatment for Adolescent and Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations
American Journal of Hematology, Volume 101, Issue 1, Page 41-55, January 2026.ABSTRACT
Asparaginase is an integral component of therapy for pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma. The success of asparaginase‐containing regimens has led to trials of pediatric/pediatric‐inspired regimens incorporating asparaginase for treating adolescent and young adult (AYA) and adult populations with acute ...Ibrahim Aldoss, Amir Ali, Ryan D. Cassaday, Emily K. Curran, Marlise R. Luskin, Luke D. Maese, Etan Orgel, Dan Douer +7 morewiley +1 more source
